Goldman Sachs Positive On Gilead Sciences (GILD) Ahead of Quad AdCom

Article Stock Quotes (1) Comments (0)

Goldman Sachs reiterated their Conviction Buy List rating and $61 price target on Gilead Sciences (NASDAQ: GILD) saying they expect a positive FDA panel vote on the company's key HIV pipeline drug.

The firm notes that on May 11 the FDA antiviral Advisory Committee will discuss
Gilead's key HIV pipeline drug, Quad, which has a PDUFA date of August 27. They expect panel documents on May 9.

Goldman expects the FDA's Advisory Committee to vote for approval of the Quad based on the strong data in two Phase III trials. This, they believe, will lift this overhang from the stock.

They see Quad as a $2bn+ drug, which could extend the tail of the company
s core HIV franchise post the patent cliff.

All this said, Goldman said the key driver of the stock remains the HepC pipeline drug '7977, which they are positive on.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $51.39 yesterday, with a 52 week range of $34.45-$56.50.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Goldman Sachs Upgrades Enbridge (ENB) to Conviction Buy
• UPDATE: Canaccord Genuity Starts T-Mobile US, (TMUS) at Hold
• UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Goldman Sachs Conviction Buy List, Goldman Sachs

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?